Full-Time
Clinical Specialist
Cardiac Rhythm Management
Posted on 8/17/2026
Medtronic
10,001+ employees
Medical device maker advancing therapies
Compensation Overview
$72k - $90k/yr
No H1B Sponsorship
Houston, TX, USA
Remote
Must reside within the assigned Houston area and travel extensively, including approximately 80% independent driving.
Bachelor's, Associate's
 Sales & Account Management (1) |
|---|
Get referred to Medtronic
See people who can refer or advise you
- A high school diploma and at least six years of work experience in healthcare, field sales, or work involving complex mathematics, mechanical concepts, science, or computing; or an associate’s degree and at least four years of such experience; or a bachelor’s degree and at least two years of such experience.
- A valid driver’s license, active auto insurance, and a driving record that meets company standards are required.
- The ability to meet vendor credentialing requirements is required.
- The ability to perform frequent two-handed lifting of up to 40 pounds, sit, stand, and walk for eight or more hours per day, and regularly bend, stoop, squat, and maintain balance is required.
- The ability to work in clinical environments with eye protection, infectious disease, and radiation exposure while wearing 7–9 pounds of lead for extended periods is required.
- The ability to use computers and mobile devices, communicate with peers and coworkers, and maintain the vision, hearing, and speaking capabilities necessary to support patient care is required.
- The ability to travel extensively by car and plane, operate a moving vehicle, and conduct business outside the typical Monday–Friday, 8:00 a.m.–5:00 p.m. schedule is required.
- Candidates below the Principal level must possess unrestricted U.S. work authorization at the time of hire and throughout employment.
- Provide technical support for Cardiac Rhythm Management devices and therapies by performing system checks and interrogations, supporting implants, troubleshooting issues, and applying knowledge from comprehensive field training.
- Coordinate operational support by ensuring accurate patient documentation, managing inventory and equipment resources, maintaining programmer software, and assisting with daily coverage logistics.
- Educate physicians, hospital staff, office personnel, and field team members on Cardiac Rhythm Management products, therapies, and solutions.
- Collaborate with sales leadership and field partners to understand customer needs, market dynamics, and the value of company products and solutions.
- Identify customer opportunities, support purchase order activities, monitor competitive trends, and provide actionable feedback to help achieve sales objectives.
- Maintain technical expertise by staying current on new products, therapies, solutions, and patient management offerings.
- Travel extensively within the assigned territory to support customer clinics, hospitals, and business meetings, with frequent independent driving of approximately 80% of the time.
- Support urgent customer needs and participate in weekend, holiday, and occasional after-hours coverage as business needs require.
- Perform the physical duties required for clinical and field-based work, including working in catheterization laboratories and operating rooms with radiation exposure and wearing a lead apron for extended periods.
- A bachelor’s degree in nursing, life sciences, or biomedical engineering is preferred.
- At least two years of experience in a catheterization laboratory, electrophysiology laboratory, hospital, or clinic with cardiology knowledge is preferred.
- Thorough working knowledge of medical terminology and the medical device industry is preferred.
- Expertise with Microsoft tools and other applications, including Salesforce.com, is preferred.
- The ability to coordinate and participate in numerous tasks and projects in a fast-paced environment while meeting deadlines is preferred.
Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Fridley, Minnesota
Founded
1949
Get referred to Medtronic
See people who can refer or advise you
Simplify's Take
What believers are saying
- FY26 revenue reached $36.4 billion; organic growth hit 5.8%, the best in ten years.
- FY27 guidance calls for 6.75%-7.25% organic growth, showing management confidence.
- Health Canada approved Affera in 2026, expanding Medtronic’s atrial fibrillation addressable market.
What critics are saying
- The August 4, 2026 $88 million mesh verdict opens thousands of similar Covidien claims.
- MiniMed priced at $20, below $25-$28, signaling weaker investor appetite for diabetes.
- Affera must convert CE Mark wins into US volume before Boston Scientific and Abbott respond.
What makes Medtronic unique
- Medtronic’s Cardiac Ablation Solutions grew 78% globally, led by Affera and PulseSelect.
- MiniMed’s 2026 IPO keeps Medtronic controlling diabetes while simplifying the portfolio.
- Forty-nine straight dividend increases signal durable cash generation and shareholder discipline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 1%Bank of America has maintained a Buy rating on Medtronic with a $95 price target, citing expectations for strong fiscal first-quarter results when the medical-device maker reports on 1 September. The company finished fiscal 2026 with $9.8 billion in fourth-quarter revenue, up 6.6% organically. Medtronic's Cardiac Ablation Solutions division posted 78% global revenue growth and 124% growth in the US, gaining eight percentage points of market share. Bank of America analyst Travis Steed expects similar growth rates to continue, potentially pushing results toward the upper end of management's 6% to 6.5% organic revenue growth guidance. However, concerns remain about sustaining momentum. Bank of America estimates CAS currently adds about three percentage points to total growth, making an eventual slowdown significant.
Craif raises $33M to accelerate introduction of its urine-based cancer test to the U.S. * 4 hrs ago SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, today announced the close of its approximately $33 million* Series D, bringing total capital raised since the company's founding to roughly $88 million**. Craif will use the proceeds to strengthen its U.S. R&D, prepare for a reimbursement-driven launch of its non-invasive cancer test in the United States and advance its Japanese regulatory filing for a software-based medical device program targeting pancreatic cancer diagnosis. The financing was co-led by Granite-Integral, a joint venture between Granite Asia and Integral Corporation, and by Tauns Co., Ltd., one of Japan's largest makers of rapid diagnostic tests. Granite Asia is a Singapore-based investment platform managing about $10 billion across the Asia-Pacific region. Integral Corporation manages approximately $3 billion and was the first Japanese private equity firm to list on the Tokyo Stock Exchange. U.S. based Unreasonable and existing investor X&KSK also participated, alongside institutional and individual investors across Singapore, the United States and Japan. The round comprised approximately $30.7 million in equity and approximately $3.3 million in debt. Founded in Japan in 2018, Craif developed a urine-based cancer detection platform that uses artificial intelligence to analyze microRNA, small regulatory molecules whose discovery and biological significance were recognized by the 2024 Nobel Prize in Physiology or Medicine. Its flagship test, miSignal, is offered at more than 2,500 medical institutions and 4,500 pharmacies across Japan, with over 110,000 tests performed to date. Craif has published more than 90 peer-reviewed papers and conference presentations, including two independent publications demonstrating the early and accurate detection of pancreatic cancer. A clinical team built for the American market A key component of Craif's plans is scaling R&D at its newly opened San Diego laboratory, including a prospective clinical study of its urine-based test in pancreatic cancer. This is an indication where the clinical utility and the path to reimbursement are clear. A simple, non-invasive urine test could help clinicians decide who needs further workup and who can safely wait. To spearhead that work, Craif has appointed Nicholas (Nick) Bevins, MD, PhD, as chief medical officer. Dr. Bevins will lead the company's clinical development strategy to build the body of evidence necessary to meet reimbursement and regulatory requirements. Dr. Bevins holds a bachelor's degree in biochemistry from Columbia University, an MD and a PhD in neuroscience from the University of California, San Diego, and completed a residency in clinical pathology and laboratory medicine. He has published more than 40 peer-reviewed papers and abstracts. He is a board-certified clinical pathologist and has served as both chief medical officer and CLIA laboratory director at several biotechnology and diagnostics companies. Because offering laboratory-developed tests in the United States requires a CLIA-certified laboratory under the oversight of a qualified laboratory director, Dr. Bevins brings a rare combination of that qualification and executive responsibility for clinical and regulatory strategy. His appointment further accelerates Craif's strategic expansion as it now advances partnerships with 30 medical institutions across 15 states. The company established a U.S. subsidiary in 2022 and joined the JLABS incubator. In April 2026, Craif opened its bio-AI laboratory in San Diego, and CEO Ryuichi Onose relocated there to lead the U.S. business. Chief Financial Officer Takeo Mukai, who previously held finance and operating leadership roles at Medtronic and several U.S. healthcare companies, also joined this year as a local hire. Quote from Ryuichi Onose, CEO and co-founder, Craif "We started Craif in 2018 to solve cancer, a problem the whole world shares, with technology built in Japan. We have brought our test to more than 2,500 clinics at home, and we are approaching a regulatory filing in pancreatic cancer. I moved to San Diego to build our U.S. business myself, because the United States is the hardest and most important market to prove this technology. What we are building goes beyond a single cancer test. The earliest signals of many diseases show up in urine, and reading them is what Craif is really about. Cancer is the first step." Quote from Nick Bevins, Chief Medical Officer "I joined Craif because the company has built a differentiated platform, generated an extraordinary body of clinical evidence in Japan, and is committed to advancing science through rigorous data rather than hype. Urine will play an increasingly important role in the future of early disease detection because it offers a non-invasive window into human biology. I look forward to collaborating with the team to make this accessible to patients." Quote from CK Chuon, Partner & Co-Head, Granite-Integral "Cancer screening should be as simple as a routine check-up, not a procedure patients avoid. Craif has proven in Japan that a non-invasive urine test can detect cancer early and at scale, and we believe the same approach can unlock massive unmet demand in the United States. We are proud to co-lead this round as Craif brings that vision to the world's largest healthcare market." Quote from Masataka Nonaka, President & Representative Director, TAUNS Laboratories, Inc. "Serving as a co-lead investor in Craif's Series D means a great deal to Mycarrollcountynews. This round will accelerate Craif's R&D, its clinical development toward regulatory approval and its global expansion. As one of Craif's distribution partners for miSignal, Mycarrollcountynews also expect the funding to move both miSignal and the pancreatic cancer SaMD program now in development closer to real-world clinical use. Craif's urine microRNA analysis technology opens new possibilities in early cancer detection and more precise diagnosis, and Mycarrollcountynews want to see it reach as many patients and healthcare institutions as possible. TAUNS will continue to support Craif's growth over the long term. Through its partnership, Mycarrollcountynews intend to help bring next-generation diagnostics into practice and contribute to solving healthcare challenges in Japan and around the world." *Total round amount, including equity investment, financing, and the secondary transaction. ¥5.28 billion at an exchange rate of ¥160.72 = $33 million. The exchange rate used is July TTM: ¥ 160.72 per USD. **Cumulative equity investment, financing, and grants since founding. Total funding raised to date: ¥14.2 billion (approximately $88 million). About Craif Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com. Forward-looking statements This release contains forward-looking statements about Craif's plans, clinical development, regulatory timelines, and business prospects. Actual results may differ materially from those expressed or implied. Craif undertakes no obligation to update these statements except as required by law. Media inquiries Craif USA, Inc.
Medtronic faces contrasting developments after a federal jury ordered it to pay $88 million in compensatory damages over injuries linked to Covidien hernia mesh in August 2026. The verdict represents a record settlement in the ongoing litigation. Meanwhile, Medtronic Canada secured Health Canada approval for its Affera Integrated Mapping and Ablation System, designed to treat atrial fibrillation and atrial flutter. The approval gives Medtronic a second pulsed field ablation platform alongside its existing PulseSelect system. The company's investment narrative projects $41.5 billion in revenue and $6.6 billion in earnings by 2029, requiring 4.5% annual revenue growth. Analysts estimate a fair value of $98.00, representing a 7% upside from current levels. However, cautious analysts forecast lower revenue of around $38.6 billion and earnings of approximately $6.2 billion by 2029, citing concerns over legal exposure and execution risks.
Medtronic has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter to treat atrial fibrillation and atrial flutter. The licence permits commercial use of Medtronic's combined pulse field and radiofrequency ablation technologies across Canada. The Affera system offers physicians an all-in-one mapping and ablation platform designed to support procedural efficiency and patient care. The approval represents a milestone for Medtronic's Cardiac Ablation Solutions division in the global atrial fibrillation treatment market. Medtronic, a US-based medical equipment company with a market capitalisation of approximately $115.9 billion, develops and sells device-based therapies to healthcare systems and clinicians globally. The approval extends Medtronic's cardiac ablation offerings from Europe and the US into Canada, where it will compete with Abbott and Boston Scientific.
Medtronic executive Shields appointed CEO at Versa Vascular. 13th August 2026 Versa Vascular, developer of a novel transcatheter tricuspid valve repair system - AdapTR - has announced changes to its senior management team and the completion of new investment to support clinical study of its device. The company announced that Bill Shields, a former vice president and general manager of Medtronic's Transcatheter Mitral and Tricuspid Therapies division joins as CEO, replacing the retiring David Hovda, who will remain as an advisor to the company. According to Versa, Shields spent 15 years with Medtronic, where he spent seven years leading product development and multiple clinical studies. Previously, he led upstream and downstream marketing for the company's transcatheter valve programs over eight years, including multiple successful product launches. The company also announced a US$15 million expansion to its series C financing, bringing the total committed capital for the round to US$42 million, supporting completion of the ongoing first-in-human clinical study of the AdapTR device outside of the USA, a US early feasibility study of the technology, and further product development and optimisation. "I am thrilled to join Versa Vascular at a time when we are seeing positive results clinically, close to expanding our clinical work to the USA, and receiving continued investor confidence," said Shields. "I have seen and launched a number of innovative transcatheter devices in my career, and the AdapTR technology shows similar promise to create a superior therapy for patients. I want to thank David Hovda and the team for their commitment to product development and refinement that has led to a truly novel solution that is showing it can have a positive impact on patients' lives." "We strongly believe in Versa's vision to improve the lives of patients with tricuspid disease, and we are proud to continue supporting the company as it executes on its clinical milestones," said Brian R Smith, founder and managing director of S3 Ventures. "We also enthusiastically welcome Bill Shields to the Versa team," said Louis A Cannon, founder of BioStar Capital. "Bill's deep structural heart expertise, experience developing new transcatheter therapies, scaling up operations, and strong industry connections align closely with BioStar's mission to improve patients' lives."